28008174|t|Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
28008174|a|In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC + R). Salvage ASCT at first relapse may still effectively rescue patients who did not receive upfront ASCT. To evaluate the long-term benefit of upfront ASCT vs CC + R and the impact of salvage ASCT in patients who received upfront CC + R, we conducted a pooled analysis of 2 phase III trials (RV-MM-209 and EMN-441). Primary endpoints were PFS1, progression-free survival 2 (PFS2), overall survival (OS). A total of 268 patients were randomized to 2 courses of melphalan 200 mg/m(2) and ASCT (MEL 200- ASCT) and 261 to CC + R. Median follow-up was 46 months. MEL 200- ASCT significantly improved PFS1 (median: 42 vs 24 months, HR 0.53; P<0.001), PFS2 (4 years: 71 vs 54%, HR 0.53, P<0.001) and OS (4 years: 84 vs 70%, HR 0.51, P<0.001) compared with CC + R. The advantage was noticed in good and bad prognosis patients. Only 53% of patients relapsing from CC + R received ASCT at first relapse. Upfront ASCT significantly reduced the risk of death (HR 0.51; P=0.007) in comparison with salvage ASCT. In conclusion, these data confirm the role of upfront ASCT as the standard approach for all young myeloma patients .Leukemia advance online publication, 24 January 2017; doi:10.1038/leu.2016.381.
28008174	0	21	Autologous transplant	T061	C0040736
28008174	25	42	oral chemotherapy	T061	C0419073
28008174	47	59	lenalidomide	T109,T121	C1144149
28008174	63	78	newly diagnosed	T080	C1518321
28008174	85	92	myeloma	T191	C0026764
28008174	93	101	patients	T101	C0030705
28008174	105	120	pooled analysis	T062	C0242481
28008174	124	139	newly diagnosed	T080	C1518321
28008174	140	147	myeloma	T191	C0026764
28008174	148	156	patients	T101	C0030705
28008174	158	187	upfront autologous transplant	T061	C0040736
28008174	189	193	ASCT	T061	C0040736
28008174	204	231	progression-free survival 1	T081	C0242792
28008174	233	237	PFS1	T081	C0242792
28008174	253	265	chemotherapy	T061	C3665472
28008174	271	283	lenalidomide	T109,T121	C1144149
28008174	285	287	CC	T061	C3665472
28008174	290	291	R	T109,T121	C1144149
28008174	294	301	Salvage	T061	C0085405
28008174	302	306	ASCT	T061	C0040736
28008174	316	323	relapse	T067	C0035020
28008174	353	361	patients	T101	C0030705
28008174	382	394	upfront ASCT	T061	C0040736
28008174	422	429	benefit	T081	C0814225
28008174	433	445	upfront ASCT	T061	C0040736
28008174	449	451	CC	T061	C3665472
28008174	454	455	R	T109,T121	C1144149
28008174	474	481	salvage	T061	C0085405
28008174	482	486	ASCT	T061	C0040736
28008174	490	498	patients	T101	C0030705
28008174	520	522	CC	T061	C3665472
28008174	525	526	R	T109,T121	C1144149
28008174	550	558	analysis	T062	C0936012
28008174	564	569	phase	T079	C1306673
28008174	574	580	trials	T062	C0008976
28008174	582	591	RV-MM-209	T062	C0242481
28008174	596	603	EMN-441	T062	C0242481
28008174	629	633	PFS1	T081	C0242792
28008174	635	662	progression-free survival 2	T081	C0242792
28008174	664	668	PFS2	T081	C0242792
28008174	671	687	overall survival	T081	C4086681
28008174	689	691	OS	T081	C4086681
28008174	709	717	patients	T101	C0030705
28008174	723	733	randomized	T062,T170	C0206034
28008174	750	759	melphalan	T116,T121	C0025241
28008174	776	780	ASCT	T061	C0040736
28008174	782	785	MEL	T116,T121	C0025241
28008174	791	795	ASCT	T061	C0040736
28008174	808	810	CC	T061	C3665472
28008174	813	814	R	T109,T121	C1144149
28008174	823	832	follow-up	T058	C1522577
28008174	840	846	months	T079	C0439231
28008174	848	851	MEL	T116,T121	C0025241
28008174	857	861	ASCT	T061	C0040736
28008174	885	889	PFS1	T081	C0242792
28008174	908	914	months	T079	C0439231
28008174	916	918	HR	T081	C2985465
28008174	935	939	PFS2	T081	C0242792
28008174	961	963	HR	T081	C2985465
28008174	983	985	OS	T081	C4086681
28008174	989	994	years	T079	C0439234
28008174	1007	1009	HR	T081	C2985465
28008174	1025	1033	compared	T052	C1707455
28008174	1039	1041	CC	T061	C3665472
28008174	1044	1045	R	T109,T121	C1144149
28008174	1089	1098	prognosis	T058	C0033325
28008174	1099	1107	patients	T101	C0030705
28008174	1121	1129	patients	T101	C0030705
28008174	1130	1139	relapsing	T067	C0035020
28008174	1145	1147	CC	T061	C3665472
28008174	1150	1151	R	T109,T121	C1144149
28008174	1161	1165	ASCT	T061	C0040736
28008174	1175	1182	relapse	T067	C0035020
28008174	1184	1196	Upfront ASCT	T061	C0040736
28008174	1223	1227	risk	T078	C0035647
28008174	1231	1236	death	T040	C0011065
28008174	1238	1240	HR	T081	C2985465
28008174	1259	1269	comparison	T052	C1707455
28008174	1275	1282	salvage	T061	C0085405
28008174	1283	1287	ASCT	T061	C0040736
28008174	1310	1314	data	T078	C1511726
28008174	1335	1347	upfront ASCT	T061	C0040736
28008174	1355	1372	standard approach	T082	C0449445
28008174	1387	1394	myeloma	T191	C0026764
28008174	1395	1403	patients	T101	C0030705